Overview: TFE3 TestIntroduction: The TFE3 Test detects TFE3 expression to diagnose renal or lung cancers, causing pain or breathing issues. Following 2023 ASH guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected renal or lung cancers.
Other Names: TFE3 Assay, TFE3 Expression Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: TFE3 testing began in the 2000s with cancer biomarker research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects TFE3 expression to diagnose renal or lung cancers, guides treatment, and evaluates patients with pain or breathing issues.
Test Parameters: 1. TFE3 Expression
Pretest Condition: No fasting required. Collect serum or plasma. Report history of pain, breathing issues, or cancer symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document pain, breathing issues, or history of renal/lung cancers. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect TFE3 expression. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for cancer diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Non-specific TFE3 expression may reduce specificity.
Clinical Significance: Positive TFE3 expression confirms renal or lung cancer, guiding targeted therapy or surgery. Negative results may require biopsy or imaging.
Specialist Consultation: Consult an oncologist or pulmonologist for result interpretation and treatment planning.
Additional Supporting Tests: Renal biopsy, CT scan, or PET scan to confirm renal/lung cancer diagnosis.
Test Limitations: Non-specific for certain cancers; clinical correlation is needed. Sample quality affects sensitivity.
References: ASH Cancer Guidelines, 2023; Journal of Clinical Oncology, Argani P, 2022.
